Carl Dambkowski Sells 5,500 Shares of Apogee Therapeutics (NASDAQ:APGE) Stock

Apogee Therapeutics Inc. (NASDAQ:APGE) insider Carl Dambkowski sold 5,500 shares of the firm’s stock in a transaction on Wednesday, February 4th. The stock was sold at an average price of $65.79, for a total value of $361,845.00. Following the transaction, the insider owned 211,148 shares of the company’s stock, valued at approximately $13,891,426.92. This represents a 2.54% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Carl Dambkowski also recently made the following trade(s):

• On Wednesday, January 7th, Carl Dambkowski sold 18,700 shares of Apogee Therapeutics stock. The stock was sold at an average price of $77.84, for a total value of $1,455,608.00.
• On Thursday, December 4th, Carl Dambkowski sold 10,900 shares of Apogee Therapeutics stock. The shares were sold at an average price of $75.00, for a total value of $817,500.00.

Apogee Therapeutics Price Performance

NASDAQ APGE opened at $62.13 on Friday. The company has a market cap of $4.24 billion, a P/E ratio of -14.18 and a beta of 1.42. The stock has a 50-day moving average of $75.27 and a two-hundred day moving average of $56.17. Apogee Therapeutics Inc. has a 1-year low of $26.20 and a 1-year high of $84.56.

Apogee Therapeutics (NASDAQ:APGE) last posted its quarterly earnings data on Monday, November 10th. The company reported ($1.11) EPS for the quarter, beating the consensus estimate of ($1.14) by $0.03. On average, analysts anticipate that Apogee Therapeutics Inc. will post -3.09 EPS for the current fiscal year.

Hedge Funds Weigh In On Apogee Therapeutics

Hedge funds have recently added to or reduced their stakes in the stock. Lisanti Capital Growth LLC purchased a new position in shares of Apogee Therapeutics during the second quarter worth approximately $800,000. Fox Run Management L.L.C. acquired a new stake in Apogee Therapeutics during the 2nd quarter worth $437,000. Allspring Global Investments Holdings LLC purchased a new position in Apogee Therapeutics during the 2nd quarter worth $218,000. Exane Asset Management acquired a new position in Apogee Therapeutics in the third quarter valued at $2,048,000. Finally, SG Americas Securities LLC purchased a new stake in shares of Apogee Therapeutics in the third quarter valued at about $5,333,000. 79.04% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of analysts have recently weighed in on APGE shares. Stifel Nicolaus set a $133.00 price objective on Apogee Therapeutics in a research report on Tuesday, January 6th. Deutsche Bank Aktiengesellschaft started coverage on Apogee Therapeutics in a report on Tuesday, December 9th. They set a “buy” rating and a $103.00 price target on the stock. Wolfe Research initiated coverage on Apogee Therapeutics in a research note on Wednesday, January 7th. They issued a “peer perform” rating for the company. Mizuho began coverage on shares of Apogee Therapeutics in a research note on Tuesday, October 21st. They set an “outperform” rating and a $105.00 target price on the stock. Finally, Stephens began coverage on shares of Apogee Therapeutics in a research note on Tuesday, December 16th. They issued an “overweight” rating and a $95.00 price target for the company. Three research analysts have rated the stock with a Strong Buy rating, eight have given a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $104.58.

Apogee Therapeutics Company Profile

Apogee Therapeutics, Inc is a clinical-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics that selectively target the nuclear receptor ROR?t, a master regulator of T cell-driven inflammatory pathways. By modulating ROR?t activity, Apogee aims to offer an oral treatment option for patients with autoimmune and inflammatory skin disorders.

The company’s lead candidate, APG-157, is an oral ROR?t inverse agonist currently undergoing early-stage clinical evaluation for moderate to severe plaque psoriasis.